RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma
2008

RASSF1A Protein Expression in Renal Cell Carcinoma

Sample size: 318 publication Evidence: moderate

Author Information

Author(s): Tezval Hossein, Merseburger Axel S, Matuschek Ira, Machtens Stefan, Kuczyk Markus A, Serth Jürgen

Primary Institution: Medizinische Hochschule Hannover

Hypothesis

The study aims to analyze RASSF1A protein expression in clear cell renal cell carcinoma and its correlation with clinicopathological parameters.

Conclusion

Most tumors show a loss of RASSF1A protein, but some exhibit substantial expression, which is associated with tumor progression and adverse clinical outcomes.

Supporting Evidence

  • RASSF1A protein expression was significantly decreased in tumor cells compared to normal cells.
  • Higher RASSF1A expression correlated with higher pT stage, histological grading, and TNM group stage.
  • A subset of tumors with normal RASSF1A levels showed a tendency towards decreased survival.

Takeaway

This study looked at a protein called RASSF1A in kidney cancer and found that while many tumors lose this protein, some still have it, which can mean the cancer is more aggressive.

Methodology

The study analyzed 318 primary clear cell carcinomas using tissue microarray analysis and immunohistochemistry, with survival analysis for 187 patients.

Limitations

The study is limited to clear cell renal cell carcinoma and may not apply to other subtypes.

Participant Demographics

Median age of follow-up group was 57.5 years, with a male-to-female ratio of 1.4:1.

Statistical Information

P-Value

p < 0.001

Confidence Interval

95% CI 0.997–1.013

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2490-8-12

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication